Stablepharma
Trending Articles
Related Content
Research & Development
Dr Steven Chatfield, an advisor to the vaccines task force during the COVID pandemic, joins Stablepharma
Stablepharma is delighted to announce that Dr Steven Chatfield, an internationally recognised expert in the field of vaccines and infectious disease, has joined the advisory board
Research & Development
Stablepharma closes series A funding round to progress fridge-free vaccines and mRNA/LNP stabilisation technologies
Stablepharma, the fridge-free vaccine company closed their series A funding round having secured £5.2 million with lead investors Hamilton Portfolio & Oval Investments, along with CrowdCube and backing of the existing shareholders
Research & Development
Accelerating vaccine development with collaboration
BB-NCIPD (Bul Bio) and Stablepharma have recently entered into a partnership to produce the world’s first fridge-free tetanus diphtheria (Td) vaccine. And, having received very encouraging potency and accelerated thermostability data from animal challenge trials, Dr Kevin Robinson spoke to Mr Roumen Kofinov, MD, General Manager of Bul Bio, and Özgür Tuncer, CEO and Executive Director of Stablepharma, to find out more